AVCNF - Retirement of Chandra Panchal PhD from the Board of Directors | Benzinga
TORONTO, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products announces today that Chandra Panchal, PhD is retiring as Chairman of the Board of Directors and that it will initiate a search for a new director.
"We wish to express our deepest thanks to Dr. Panchal for all his time and all of his efforts during these past seven years that he has served as a member of the Board of Directors of the Company. During his tenure with Avicanna, Dr. Panchal witnessed our evolution from a pre-commercial R&D-stage company into an international biopharmaceutical company and assisted management with various external challenges and internal growing pains along the way," stated Aras Azadian, CEO.
"It was an honor to have served as Chairman of the Board these past years. With the Company recently closing a transformational acquisition, launching MyMedi.ca, and reporting record revenues, I am proud of the Company's management and employees who have developed Avicanna from a fledgling start-up to an international player in a short period of time. I believe now is the right time for me to retire from active board service at the Company," stated Chandra Panchal, PhD.
About Avicanna Inc.
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an ...